NCT05846516CompletedPhase 1
KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Jun 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- First submitted
- 6 Oct 2023
- Start date
- 5 Feb 2025
- Lead sponsor
- Boehringer Ingelheim International GmbH
- Diseases
- Pancreatic cancer
- NCT number
- NCT05846516
- EU CT number
- 2022-501854-12-01
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 37
- 9 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Asklepios Kliniken Hamburg GmbH Coordinator of this site? Confirm its status | Hamburg | Germany | Completed |
| Universitaetsklinikum Heidelberg AöR Coordinator of this site? Confirm its status | Heidelberg | Germany | Completed |
| Hospital Universitari Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Completed |
| Hospital Universitario Reina Sofia Coordinator of this site? Confirm its status | Córdoba | Spain | Completed |
| Hospital General Universitario Gregorio Marañón Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| Hospital Universitario Fundación Jiménez Díaz Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| Hospital Universitario HM Sanchinarro Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| Institut Curie Coordinator of this site? Confirm its status | Paris | France | Completed |
| Institut Gustave Roussy Coordinator of this site? Confirm its status | Villejuif | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.